Leukemia Clinical Trials

Showing 1281-1300 of 10,987 trials

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

NCT06660368

This multicenter, open-label phase II study combines CLAG-based therapy with or without venetoclax in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) in order to improve measurable residual disease (MRD) clearance and event-free survival. Investigators hypothesize that the addition of venetoclax to CLAG-M in patients with relapsed or refractory AML is safe, and superior to CLAG-M alone in improving patient outcomes.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

H. Lee Moffitt Cancer Center and Research Institute52 participantsStarted Nov 2024

Tampa, Florida, United States • Boston, Massachusetts, United States

RECRUITINGPhase 1/2

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06974812

This is a phase 1/2 multicenter, multi-regional, open-label, first-in-human study of IBI3014 in participants with unresectable locally advanced or metastatic solid tumors.

Unresectable Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.250 participantsStarted Apr 2025

Fuzhou, Fujian, China • Changsha, Hunan, China • Shanghai, Shanghai Municipality, China

Not Yet RecruitingPhase 2

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

NCT07376499

To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction

Small Cell Lung Cancer

China Medical University, China31 participantsStarted Jan 2026

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction

Related Searches

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Breast Cancer

Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC

Venetoclax Plus Inotuzumab for B-ALL

Diet, Hepcidin, and Chemotherapy RDI

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

Assessing Diet, Stress Scores, and Other Health Metrics in Healthy Northern California Adults

To Evaluate Early (2-Week) vs. Standard (4-Week) Metal Stent Removal Following Endoscopic Ultrasound Guided WON Drainage

A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

Research on the Individualized Treatment Strategy for Extremely Preterm Infants With hsPDA Based on Biomarkers and Targeted Delivery Systems

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms